| HLT |
Report |
System-wide RevPAR Growth (Q2 2026) |
MISS |
pred ~+3.0% vs. cons +3.38% |
MEDIUM |
| HLT |
Report |
Adj. EBITDA (Q2 2026) |
BEAT |
pred ~$1,050M vs. cons $1,039M |
MEDIUM |
| HLT |
Report |
Diluted EPS - Operating (Q2 2026) |
IN-LINE |
pred ~$2.30 vs. cons $2.28 |
MEDIUM |
| HLT |
Guide |
FY 2026 RevPAR Growth (FY 2026) |
UNCHANGED |
guide ~2-3% vs. cons +2.79% |
HIGH |
| HLT |
Guide |
FY 2026 Adj. EBITDA (FY 2026) |
UNCHANGED |
guide ~$4,020-4,060M vs. cons $4,054M |
HIGH |
| HLT |
Guide |
FY 2026 Diluted EPS - Operating (FY 2026) |
LOWER |
guide ~$8.79-8.91 vs. cons $8.98 |
HIGH |
| HLT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| HLT |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — sell-side cuts FY EPS estimates as guide range ($8.79-8.91) remains below consensus ($8.98); implicit H2 EBITDA cut of ~$25M drives continued underperformance |
MEDIUM |